Huixquilucan De Degollado

Researchers are evaluating treatments for adults with relapsed or refractory multiple myeloma who have previously received an anti-CD38 antibody and lenalidomide. The study compares the effectiveness of talquetamab combined with pomalidomide (Tal-P), talquetamab combined with teclistamab (Tal-Tec), and investigator's choice between two standard regimens: elotuzumab with pomalidomide and dexamethasone (EPd), or pomalidomide with bortezomib and dexamethasone (PVd). This Phase 3 trial aims to understand which combination best controls the disease progression. Participants will receive talquetamab as a subcutaneous injection, pomalidomide orally, teclistamab as a subcutaneous injection, elotuzumab intravenously, dexamethasone either orally or intravenously, and bortezomib as a subcutaneous injection. The study involves comparing these combinations with varying administration routes. The trial includes multiple treatment arms to assess different drug combinations in patients who have undergone 1 to 4 prior therapies. During the study, participants will be monitored for progression-free survival up to 3 years and 5 months. Researchers will regularly assess disease status, treatment response, and safety. Participants' performance status will be evaluated, and adherence to treatment and potential side effects will be carefully tracked. This long-term observation will help determine how well each treatment combination controls the disease over time.

Researchers are investigating the safety and effectiveness of eloralintide compared to a placebo in adults with persistent obesity or overweight. This includes people with or without type 2 diabetes who are already on stable weekly incretin therapy. The study is a phase 3, randomized, double-blind trial focusing on this specific group to better understand treatment outcomes. Participants will receive either eloralintide or a placebo, both given by subcutaneous injection once a week. The study compares these two treatments over the course of the trial. Participants must continue their stable incretin therapy throughout the study period. The study lasts about 80 weeks in total. Researchers will monitor changes in body weight from the start of treatment to week 64 as the main outcome. Participants will have regular assessments to track their health, safety, and treatment effects during this time.

Researchers are evaluating finerenone, a drug that blocks a protein involved in inflammation and scarring, to see if it helps children with heart failure and left ventricular systolic dysfunction (LVSD). Heart failure is a serious condition where the heart cannot pump enough blood, causing symptoms like shortness of breath, fatigue, and poor growth. This Phase 3 study is the first to explore finerenone's effects specifically in children aged 6 months to under 18 years with these heart problems. The goal is to determine if finerenone improves heart function compared to a placebo by measuring levels of a heart stress protein called NT-proBNP and monitoring safety. Participants will be randomly assigned to receive either finerenone or a placebo for about 90 days, while continuing their standard heart failure treatments. The study includes a double-blind design, meaning neither the participants nor the researchers know who receives the active drug or placebo during this period. After the initial three-month treatment, eligible participants may join a nine-month open-label extension where all receive finerenone. Those not entering the extension will have a follow-up visit 30 days after finishing treatment. Throughout the study, participants will visit the study site at least three times for assessments including vital signs, heart exams with ECG and echocardiogram, blood tests, physical exams, and interviews about their medication and any medical problems. Researchers will track all adverse events, which are any health issues occurring during the study, regardless of relation to the treatment. The main outcome measured is the change in NT-proBNP from the start to the end of treatment, helping to evaluate the drug's effect on heart stress.

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer affecting white blood cells, and it is the most common form of non-Hodgkin lymphoma. Follicular lymphoma (FL) is a slower-growing type of this lymphoma. This study aims to evaluate the real-world effectiveness of the investigational drug epcoritamab in adult patients with advanced DLBCL and FL. Around 700 participants will be enrolled across approximately 80 sites in 12 to 20 countries worldwide. Participants will receive epcoritamab as prescribed by their doctors according to the approved treatment guidelines in their country. The study does not add any extra treatments or procedures beyond what their doctors recommend. Participants will be followed for up to about 3 years to observe their responses to the treatment. During the study, participants will attend regular visits at hospitals or clinics as part of their standard care routine. Researchers will track the percentage of participants who achieve an overall response to treatment over the study period. There is no expected additional burden for participants beyond their usual clinical visits and treatments.

Researchers are investigating treatments for older adults newly diagnosed with Philadelphia-negative B-cell precursor acute lymphoblastic leukemia (ALL). The study includes a safety run-in phase to assess the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 portion compares event-free survival and overall survival between participants receiving blinatumomab combined with low-intensity chemotherapy and those receiving standard of care chemotherapy. Participants receive blinatumomab through continuous intravenous infusion alternating with a low-intensity chemotherapy regimen, which may be given by intravenous, oral, subcutaneous, or intrathecal methods. The comparison group receives standard of care chemotherapy administered by similar routes. The study includes a safety run-in period followed by a randomized controlled phase to evaluate outcomes over approximately five years. During the study, participants undergo regular assessments including monitoring for treatment-emergent adverse events, event-free survival, and overall survival for up to five years. Researchers monitor organ function and overall health status throughout the trial. The study includes long-term follow-up to evaluate the safety and effectiveness of the treatments over time, with detailed evaluations to ensure participant safety and treatment adherence.